US Senate targets ‘patent thickets,’ but supporters say it isn't enough
By Nick Robertson ( July 23, 2026, 21:39 GMT | Comment) -- The Senate passed the Affordable Prescriptions for Patients Act by unanimous consent this week, approving a cap on the number of patents asserted in biosimilar litigation. Supporters say the vote reflects growing congressional willingness to address so-called "patent thickets," even as some advocates argue that the bill is too limited in scope.The Senate passed a bill this week that would limit the number of patents a pharmaceutical company can assert in biosimilar patent litigation, a sign of momentum for further “patent thicket” reform, advocates argue....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.